Bioceltix plans to achieve EU Good Manufacturing Practise certification by the end of 2019. This certificate entitles to start the production process of the first candidates for medicines. The company is trying to obtain it for stem cell-based medicines for dogs suffering from atopic dermatitis and cancer changes such as leukaemia or lymphoma. “By the end of the year we are trying to obtain the GMP certificate. We also plan to complete the validation process for our remaining drug candidates,” said Jakub Grzesiak, Director and Head of Research & Development at Bioceltix. At the beginning of this year, Boehringer Ingelheim Animal Health commercialized its stem cell product. According to Łukasz Bzdzion, CEO of Bioceltix, the first stem cell product was commercialized, thus paving the way for other companies planning to enter the market. Bioceltix is currently developing four biopharmaceutical products to be launched in 2022.
